Scholarlink

<p>Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by the accumulation of amyloid-β, hyperphosphorylation of tau, oxidative stress, synaptic dysfunction, and neuroinflammation. Recent research underscores the Forkhead box O (FOXO) family of transcription factors (FOXO1, FOXO3, FOXO4, FOXO6) as crucial regulators of these pathogenic processes. FOXOs regulate antioxidant defenses, autophagy, mitochondrial quality control, and apoptosis by functioning downstream of insulin/PI3K–Akt and stress-responsive pathways. This context-dependent activity enables FOXOs to act as dual regulators: brief activation improves proteostasis, oxidative stress tolerance, and synaptic resilience, whereas dysregulated signaling triggers pro-apoptotic and neurodegenerative pathways. Genetic and pharmacological studies targeting FOXO signaling highlight its potential as a therapeutic target; nonetheless, obstacles persist, including isoform specificity, compensatory feedback mechanisms, and transport across the blood-brain barrier. This review consolidates contemporary understanding of the structural and functional functions of FOXO isoforms in AD, their participation in amyloid and tau pathology, oxidative stress, and neuroinflammation, and assesses options for therapeutic control. A deeper understanding of FOXO signaling could lead to novel therapies that utilize its neuroprotective properties specifically, while minimizing adverse effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FOXO transcription factors in Alzheimer’s Disease: balancing neuroprotection and neuronal degeneration

  • 期刊论文

  • 发表日期：

    2026年5月26日

查看全文
  • Mukul Shyam,
  • Aleen Veronica,
  • Jyoti Wadhwa,
  • Vidhi Sharma,
  • Oveyaa B M,
  • Prathap Srirangan,
  • Rajendran Venkatesh,
  • Sabina Evan Prince

摘要

Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by the accumulation of amyloid-β, hyperphosphorylation of tau, oxidative stress, synaptic dysfunction, and neuroinflammation. Recent research underscores the Forkhead box O (FOXO) family of transcription factors (FOXO1, FOXO3, FOXO4, FOXO6) as crucial regulators of these pathogenic processes. FOXOs regulate antioxidant defenses, autophagy, mitochondrial quality control, and apoptosis by functioning downstream of insulin/PI3K–Akt and stress-responsive pathways. This context-dependent activity enables FOXOs to act as dual regulators: brief activation improves proteostasis, oxidative stress tolerance, and synaptic resilience, whereas dysregulated signaling triggers pro-apoptotic and neurodegenerative pathways. Genetic and pharmacological studies targeting FOXO signaling highlight its potential as a therapeutic target; nonetheless, obstacles persist, including isoform specificity, compensatory feedback mechanisms, and transport across the blood-brain barrier. This review consolidates contemporary understanding of the structural and functional functions of FOXO isoforms in AD, their participation in amyloid and tau pathology, oxidative stress, and neuroinflammation, and assesses options for therapeutic control. A deeper understanding of FOXO signaling could lead to novel therapies that utilize its neuroprotective properties specifically, while minimizing adverse effects.